ACTI Stock Overview
A biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Active Biotech AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.26 |
| 52 Week High | SEK 1.48 |
| 52 Week Low | SEK 0.15 |
| Beta | 0.48 |
| 11 Month Change | -11.11% |
| 3 Month Change | -43.74% |
| 1 Year Change | -49.31% |
| 33 Year Change | -80.92% |
| 5 Year Change | -89.94% |
| Change since IPO | -99.22% |
Recent News & Updates
Recent updates
Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation
Jun 05
Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?
Feb 19Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely
Jul 27Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely
May 07Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation
Nov 09We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely
May 03We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate
Jan 18
Shareholder Returns
| ACTI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -12.3% | -8.0% | -2.4% |
| 1Y | -49.3% | 12.6% | 10.9% |
Return vs Industry: ACTI underperformed the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: ACTI underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| ACTI volatility | |
|---|---|
| ACTI Average Weekly Movement | 30.0% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: ACTI's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ACTI's weekly volatility has increased from 18% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 6 | Helen Tuvesson | www.activebiotech.com |
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that has completed phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Active Biotech AB (publ) Fundamentals Summary
| ACTI fundamental statistics | |
|---|---|
| Market cap | SEK 314.92m |
| Earnings (TTM) | -SEK 41.60m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.6x
P/E RatioIs ACTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACTI income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 41.60m |
| Earnings | -SEK 41.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACTI perform over the long term?
See historical performance and comparison